Vimarsana
Biggest News Aggregation in the World

Page 15 - Lantern Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lantern Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lantern Pharma Today - Breaking & Trending Today

Lantern Pharma Announces Extension of Existing Share Repurchase Program - Vimarsana News

Lantern Pharma Announces Extension of Existing Share Repurchase Program

Published: March 22, 2022

/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and...

Source: prnewswire.com
Related Topics:
United StatesNicole LeberExchange CommissionExchange Commission OnPrnewswire Lantern Pharma IncSecurities ExchangeUnited States SecuritiesSecurities ActSecurities Exchange ActRisk FactorsAnnual ReportLantern Pharma
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights - Vimarsana News

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

Published: March 10, 2022

/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and...

Source: prnewswire.com
Related Topics:
United StatesNicole LeberNational Cancer InstituteExchange Commission OnSociety For NeuroAmerican Society Of HematologyGreehey Children Cancer Research InstituteRare Pediatric Disease Priority Review Voucher ProgramUniversity Of Texas Health Science Center San AntonioJohns Hopkins Kennedy Krieger InstituteDanish Cancer Society Research CenterAmerican Association For Cancer ResearchPrnewswire Lantern Pharma IncSecurities ExchangeFox Chase Cancer CenterLantern PharmaPanna SharmaClinical TrialPlatform GrowthAntibody Drug ConjugateDrug DesignationsRare Pediatric Disease DesignationDrug ConjugateGreehey ChildrenCancer Research Institute
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights - Vimarsana News

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

Published: March 10, 2022

/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and...

Source: prnewswire.com
Related Topics:
United StatesNicole LeberNational Cancer InstituteExchange Commission OnSociety For NeuroAmerican Society Of HematologyGreehey Children Cancer Research InstituteRare Pediatric Disease Priority Review Voucher ProgramUniversity Of Texas Health Science Center San AntonioJohns Hopkins Kennedy Krieger InstituteDanish Cancer Society Research CenterAmerican Association For Cancer ResearchPrnewswire Lantern Pharma IncSecurities ExchangeFox Chase Cancer CenterLantern PharmaPanna SharmaClinical TrialPlatform GrowthAntibody Drug ConjugateDrug DesignationsRare Pediatric Disease DesignationDrug ConjugateGreehey ChildrenCancer Research Institute
North Texas Healthcare Is a $52 Billion Economic Force - Vimarsana News

North Texas Healthcare Is a $52 Billion Economic Force

Published: January 24, 2022

The region's wide-ranging healthcare industry represents about 15 percent of the local economy.

Source: dmagazine.com
Related Topics:
Pegasus ParkUnited StatesFort WorthNorth Richland HillsNew MexicoTexas CollegeSouthlake OnconanoBaylor Scott WhiteHubert ZajicekSchool Of MedicineChristus HealthTexas College Of Osteopathic MedicineHealth Science CenterBureau Of Labor StatisticsParkland HealthTexas National GuardHealth WildcattersFort Worth Hospital CouncilTexas Military DepartmentResearch Institute Of TexasInnovation CommunityDallas Regional ChamberChristian UniversityTexas Health ResourcesBaylor Scott White Health
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors - Vimarsana News

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

Published: January 18, 2022

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

Source: prnewswire.com
Related Topics:
United StatesMef NilbertZoltan SzallasiExchange Commission OnDrug AdministrationHarvard Medical SchoolDanish Cancer Society Is DenmarkDanish Cancer Society Research CenterLantern Pharma IncSecurities ExchangeDanish Cancer SocietyRedchip CompaniesComputational Health Informatics ProgramLantern PharmaDanish CancerGroup LeaderTranslational Cancer GenomicsAssistant ProfessorBoston ChildrenHarvard MedicalPanna SharmaOrphan Drug DesignationResponse AlgorithmDrug PositioningSecurities Act